Dioseve develops co-culture in vitro maturation products using ovarian support cell-like cells derived from iPS cells.
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Series A Dioseve raised over 1 billion yen in a Series A extension led by Archetype Ventures to advance its iPS cell-based in vitro maturation product. | $6.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.